Newswire (Published: Tuesday, July 4, 2017, Received: Thursday, June 29, 2017, 9:49:04 PM CDT)
Word Count: 506
By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating in New Haven, Connecticut, by NewsRx journalists, research stated, "PurposeThe suitability of younger patients with prostate cancer (PCa) for initial active surveillance (AS) has been questioned on the basis of eventual treatment necessity and concerns of safety; however, the role of age on surveillance outcomes has not been well defined.Patients and MethodsWe identified men managed with AS at our institution with a minimum follow-up of 6 months. The primary study objective was to examine the association of age with risk of biopsy-based Gleason score upgrade during AS."
The news reporters obtained a quote from the research from Yale University, "We also examined the association of age with related end points, including overall biopsy-determined progression, definitive treatment, and pathologic and biochemical outcomes after delayed radical prostatectomy (RP), using descriptive statistics, the Kaplan-Meier method, and multivariable Cox proportional hazards regression.ResultsA total of 1,433 patients were followed for a median of 49 months; 74% underwent initial biopsy at a referring institution. Median age at diagnosis was 63 years, including 599 patients (42%) 60 years old and 834 (58%) > 60 years old. The 3- and 5-year biopsy-based Gleason score upgrade-free rates were 73% and 55%, respectively, for men 60 years old compared with 64% and 48%, respectively, for men older than 60 years (P < .01). On Cox regression analysis, younger age was independently associated with lower risk of biopsy-based Gleason score upgrade (hazard ratio per 1-year decrease, 0.969 [95% CI, 0.956 to 0.983]; P< .01), and persisted upon restriction to men meeting strict AS inclusion criteria. There was no significant association between younger age and risk of definitive treatment or risk of biochemical recurrence after delayed RP.ConclusionYounger patient age was associated with decreased risk of biopsy-based Gleason score upgrade during AS but not with risk of definitive treatment in the intermediate term."
According to the news reporters, the research concluded: "AS represents a strategy to mitigate overtreatment in young patients with low-risk PCa in the early term."
For more information on this research see: Active Surveillance in Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2017;35(17):1898-1904,52-56. Journal of Clinical Oncology can be contacted at: Amer Soc Clinical Oncology, 2318 Mill Road, Ste 800, Alexandria, VA 22314, USA (see also Oncology - Prostate Cancer).
Our news correspondents report that additional information may be obtained by contacting M.S. Leapman, Yale University, Sch Med, New Haven, CT, United States. Additional authors for this research include J.E. Cowan, H.G. Nguyen, K.K. Shinohara, N. Perez, M.R. Cooperberg, W.J. Catalona and P.R. Carroll.
Keywords for this news article include: New Haven, Connecticut, United States, North and Central America, Chemicals, Epidemiology, Prostatic Neoplasms, Prostate Cancer, Biochemicals, Biochemistry, Oncology, Yale University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues